Soluble RANKL in Crevicular Fluid of Dental Implants: A Pilot Study
- 16 August 2006
- journal article
- Published by Wiley in Clinical Implant Dentistry and Related Research
- Vol. 8 (3), 135-141
- https://doi.org/10.1111/j.1708-8208.2006.00012.x
Abstract
Receptor activator of NF-kappaB ligand (RANKL), a member of the tumor necrosis factor superfamily, is a key mediator of osteoclast formation, activation, and survival. Thus, it is reasonable to hypothesize that there might be a functional relationship between RANKL expression and peri-implantitis. This pilot study was performed to determine the reference levels for soluble RANKL (sRANKL) in peri-implant crevicular fluid and to correlate them with the clinical parameters associated with inflammatory reactions and bone destruction. The clinical parameters probing depth (PD), modified bleeding index (MBI), and modified plaque index (MPI) served as indicators for bone resorption and inflammation. Exclusion criteria for calculations were the detection limit of the immunoassay and the minimum acceptable crevicular volume for measurement. From the 84 collected samples of 16 patients, 30-84 years of age, with a total of 19 implants, 29 met these criteria. The absolute amount of sRANKL within crevicular fluid adsorbed to filter strips was a median of 0.18 femtomol (fmol; range, 0.08-0.53) and 0.26 nM (range, 0.09-1.21) when normalized by volume. PD was 4 mm in median and varied within a range between 2 and 12 mm. Absolute amounts of sRANKL showed no correlation with the adsorbed volume and the clinical parameters PD, MBI, and MPI. When sRANKL was normalized by volume, no correlation with the clinical parameters PD, MBI, and MPI was observed either. The patients' age was not associated with total sRANKL and the concentration of RANKL within crevicular fluid. Absolute levels of sRANKL and sRANKL concentration did not show any differences based on the sampling sites buccal and lingual, or on the patients' gender. A significant difference in sRANKL concentration was detectable when samples from maxillary implants (0.31 nM median; range, 0.12-1.21) were compared with samples from mandibular implants (0.21 nM median; range, 0.09-0.6) (p=.03). Absolute levels of sRANKL were not different between the maxilla and the mandible. Given the limited sample size, our data provide a basis for future prospective longitudinal studies on the possible relevance of sRANKL as a prognostic marker in peri-implantitis, and for an understanding of the pathophysiologic process of the disease as a prerequisite for the design of treatment strategies.Keywords
This publication has 32 references indexed in Scilit:
- The impact of new biologicals in the treatment of rheumatoid arthritisRheumatology, 2004
- Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacementThe Journal of Bone and Joint Surgery. British volume, 2003
- Osteoclast differentiation and activationNature, 2003
- Laminin‐5 γ2‐chain and collagenase‐2 (MMP‐8) in human peri‐implant sulcular fluidClinical Oral Implants Research, 2003
- Interleukin‐1β, tumor necrosis factor‐α levels and neutrophil elastase activity in peri‐implant crevicular fluidClinical Oral Implants Research, 2002
- High levels of osteoprotegerin and soluble receptor activator of nuclear factor κB ligand in serum of rheumatoid arthritis patients and their normalization after anti–tumor necrosis factor α treatmentArthritis & Rheumatism, 2002
- TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligandJCI Insight, 2000
- Interleukin-1β and tumor necrosis factor-α, but not interleukin-6, stimulate osteoprotegerin ligand gene expression in human osteoblastic cellsBone, 1999
- Biological aspects of implant dentistry: osseointegrationPeriodontology 2000, 1994
- Periodontal Disease in Pregnancy II. Correlation Between Oral Hygiene and Periodontal ConditionActa Odontologica Scandinavica, 1964